August 6, 2024 Source: drugdu 126
SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ("Porton Advanced") announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both sides will combine their respective strengths in the field of gene therapy to jointly provide better drug development services. Leveraging Porton Advanced's end-to-end cell and gene therapy CDMO service platform and resource advantages, combined with Geneseed Biotech's comprehensive core patented technologies in circRNA drug concept validation and process development, the two companies will jointly propel technological innovation and clinical translation, thereby accelerating the implementation of innovative circRNA therapies.
Proton Advanced is committed to providing end-to-end CDMO services for cell and gene therapy, and has extensive experience in nucleic acid therapy process development and GMP production, covering various types including mRNA, saRNA, circRNA, and more. Porton Advanced can provide comprehensive CMC services from preclinical to clinical production. Geneseed Biotech, relying on its profound technology and robust original R&D capability, has broken through the technical bottleneck of circRNA drug development and possesses independent intellectual property rights over its core circularization technology. In this cooperation, both parties will establish a comprehensive strategic partnership to deeply expanding technological cooperation and resource sharing in the field of circRNA. This will further strengthen Porton Advanced's end-to-end CDMO platform, from innovation in research and technology to high-quality project delivery, thereby providing more valuable services to customers.
"We are very pleased to have entered into a strategic collaboration with Porton Advanced." said Liu Ming, founder and CEO of Geneseed Biotech. "CircRNA is recognized by the industry to be the next-generation RNA platform for vaccines, rare disease therapies, and anti-tumor therapies due to its high stability, low immunogenicity and cost-effective production in drug development. As a pioneering leader in circular RNA research and development, Geneseed Biotech has consistently delved deep into this area, ranging from scientific research to drug development, catering to the evolving demands of our customers. Porton Advanced possesses extensive service experience and profound technical expertise in CGT. Our collaboration across the industrial chain can fully leverage each other's professional and resource strengths, facilitating the development of circRNA drugs and accelerating the industrialization of circRNA technology."
"Collaborating with upstream and downstream enterprises across the industrial chain to realize win-win cooperation and deliver more valuable services to our customers is the core significance of Porton Advanced's efforts in constructing a vibrant CGT ecosystem." said Chen Hui, CFO of Porton Advanced. "We are delighted to forge a strategic partnership with Geneseed Biotech, an excellent CRO enterprise. Geneseed Biotech possesses robust and innovative RNA synthesis technologies, coupled with extensive project experience and platform advantages in the scientific research and application translation of circRNA. By integrating our respective technological strengths and platform resources, we aim to further refine and enhance platform capabilities of Porton Advanced, providing comprehensive CRDMO solutions for the development of innovative RNA therapeutics from early-stage research to clinical and commercial production, empowering our global customers."
https://en.prnasia.com/releases/global/porton-advanced-and-geneseed-biotech-enter-into-strategic-collaboration-to-focus-on-advancing-circrna-innovative-therapeutics-455772.shtml
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.